Tilray Inc

Summer 2018 was a season of surprises – mostly great ones – for cannabis investing.

Not long ago, few foresaw Corona's parent corporation Constellation Brands investing $3.8 million in what was already the world's biggest cannabis producer in its second deal together in less than a year…

Or Coca-Cola Co. starting negotiations with a cannabis company about a potential CBD-based beverage…

Or a British pharmaceutical developer getting the first U.S. Food & Drug Association approval for a cannabis-based medicine. 

Yet every one of those events happened… in short order.

With each time, cannabis stocks soared accordingly, especially for the companies directly involved.

Big news means major moves when it comes to cannabis investing.

But what I see as the biggest, most shocking developments of late haven't been happening in a board room. They've been happening in the shadows of the Capitol in Washington, D.C.

The U.S. cannabis policy thaw is already underway, and the ongoing developments associated with it are going to be game changers for investors who don't wait for too long on the sidelines.

These are first-time events that herald a brand-new era of cannabis profits for shareholders.

We're talking about real movement in the slow and steady end of the longtime federal prohibition of marijuana.